Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00328692
Status:
COMPLETED
Last Update Posted:
2009-10-09
First Post:
2006-05-19
Brief Title:
PROTECT-1 A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
Sponsor:
NovaCardia Inc a subsidiary of Merck Co Inc Rahway New Jersey USA
Organization:
NovaCardia Inc a subsidiary of Merck Co Inc Rahway New Jersey USA
Study Overview
Official Title:
A Multicenter Randomized Double-blind Placebo-controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms and Renal Function in Subjects With Acute Heart Failure Syndrome and Renal Impairment Who Are Hospitalized for Volume Overload and Require Intravenous Diuretic Therapy
Status:
COMPLETED
Status Verified Date:
2009-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure with less treatment failure than standard therapy when it is added to IV loop diuretics in subjects with acute heart failure syndrome and renal impairment
Detailed Description:
Loop diuretics are generally first line therapy in patients hospitalized with acute heart failure syndrome AHFS Their use far exceeds that of vasoactive agents Tubuloglomerular feedback TGF is the bodys compensatory response to avoid excess fluid loss and it is activated when elevated sodium concentrations in the distal tubule are detected TGF is proposed as a contributing factor for the observed diuretic resistance that occurs in patients with heart failure Higher doses of diuretics are required to overcome the decreased natriuresis and reduced RBF induced by TGF Ultimately this action creates a vicious cycle of worsening renal function and diminished diuretic effectiveness
The primary pharmacologic rationale for the use of KW-3902 in subjects with AHFS is its mechanism of action as an adenosine A1 receptor antagonist TGF promotes release of adenosine and adenosine binding to A1 receptors causes vasoconstriction of the afferent arteriole decreased RBF and enhanced sodium reabsorption by the proximal tubule This action results in a decrease in GFR diminished renal function and sodium and water retention Blocking adenosine A1 receptors via a selective adenosine receptor antagonist may limit sodium reabsorption by the proximal tubules without triggering TGF It promotes vasodilation of the afferent arteriole of the glomerulus and thus this strategy offers the potential to overcome diuretic resistance or enhance diuretic responsiveness It may also reduce the need for increasing diuretic doses that have been associated with worse outcomes
The objectives of this study are to evaluate the effect of KW-3902IV in addition to intravenous IV loop diuretics such as furosemide on heart failure signs and symptoms renal function and safety in subjects hospitalized with AHFS volume overload and renal impairment and to estimate and compare within-trial medical resource utilization and direct medical costs between patients treated with KW-3902IV versus placebo
The primary pharmacologic rationale for the use of KW-3902 in subjects with AHFS is its mechanism of action as an adenosine A1 receptor antagonist TGF promotes release of adenosine and adenosine binding to A1 receptors causes vasoconstriction of the afferent arteriole decreased RBF and enhanced sodium reabsorption by the proximal tubule This action results in a decrease in GFR diminished renal function and sodium and water retention Blocking adenosine A1 receptors via a selective adenosine receptor antagonist may limit sodium reabsorption by the proximal tubules without triggering TGF It promotes vasodilation of the afferent arteriole of the glomerulus and thus this strategy offers the potential to overcome diuretic resistance or enhance diuretic responsiveness It may also reduce the need for increasing diuretic doses that have been associated with worse outcomes
The objectives of this study are to evaluate the effect of KW-3902IV in addition to intravenous IV loop diuretics such as furosemide on heart failure signs and symptoms renal function and safety in subjects hospitalized with AHFS volume overload and renal impairment and to estimate and compare within-trial medical resource utilization and direct medical costs between patients treated with KW-3902IV versus placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MK7418-301 | None | None | None |
| 2007_803 | None | None | None |